Prognostic impact of 18F-FDG PET/CT in patients with multiple myeloma presenting with renal impairment

被引：0

作者：

Ahn, Seo-Yeon ^{[1
]}

Park, Hwa Kyung ^{[1
]}

Moon, Joon Ho ^{[2
]}

Baek, Dong Won ^{[2
]}

Cho, Hee-Jeong ^{[2
]}

Sohn, Sang Kyun ^{[2
]}

Kang, Sae-Ryung ^{[3
]}

Min, Jung-Joon ^{[3
]}

Bom, Hee-Seung ^{[3
]}

Hong, Chae Moon ^{[4
]}

Jeong, Shin Young ^{[5
]}

Song, Ga-Young ^{[1
]}

Yang, Deok-Hwan ^{[1
]}

Ahn, Jae-Sook ^{[1
]}

Kim, Hyeoung-Joon ^{[1
]}

Jung, Sung-Hoon ^{[1
]}

Lee, Je-Jung ^{[1
]}

机构：

[1] Chonnam Natl Univ, Dept Hematol Oncol, Hwasun Hosp, 322 Seoyangro, Hwasun 519763, Jeollanamdo, South Korea

[2] Kyungpook Natl Univ Hosp, Dept Hematol Oncol, Daegu, South Korea

[3] Chonnam Natl Univ, Dept Nucl Med, Hwasun Hosp, 322 Seoyangro, Hwasun 519763, Jeollanamdo, South Korea

[4] Kyungpook Natl Univ Hosp, Dept Nucl Med, Daegu, South Korea

[5] Kyungpook Natl Univ, Dept Nucl Med, Chilgok Hosp, Daegu, South Korea

来源：

INTERNATIONAL JOURNAL OF HEMATOLOGY | 2021年 / 113卷 / 05期

关键词：

Multiple myeloma; Renal insufficiency; Positron emission tomography; Prognosis; INTERNATIONAL STAGING SYSTEM; POSITRON-EMISSION-TOMOGRAPHY; FDG PET/CT; FAILURE; STATEMENT; DIAGNOSIS; SURVIVAL; DIALYSIS; OUTCOMES; DISEASE;

D O I：

10.1007/s12185-021-03079-w

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Renal insufficiency (RI) is a frequent manifestation of multiple myeloma (MM) at time of diagnosis but there is no reliable prognostic factor for patients with MM presenting with RI. This study investigated the prognostic impact of F-18-fluorodeoxyglucose (F-18-FDG) positron emission tomography/computed tomography (PET/CT) in patients with MM with RI at diagnosis. The records of 209 patients with MM between June 2011 and November 2018 were retrospectively analyzed. PET/CT positivity was defined as the presence of more than three focal lesions or the presence of extramedullary disease. Of 209 patients, 90 (43.1%) had RI and showed similar survival outcomes to patients who had normal renal function. In total, 113 patients (54.0%) were PET/CT-positive, and 46.6% of patients with RI were PET/CT-positive at baseline. In patients with RI, those who were PET/CT-positive showed significantly inferior survival outcomes to those who were PET/CT-negative [progression-free survival (PFS), 12.7 vs. 34.0 months, P < 0.001; overall survival (OS), 42.2 months vs. not reached, P = 0.001]. On multivariate analysis, PET/CT positivity was significantly associated with PFS and OS in patients with RI. In conclusion, PET/CT is a reliable imaging technique for predicting survival outcomes in patients with MM with RI.

引用

页码：668 / 674

页数：7

共 29 条

[1] 18F-FDG uptake and clearance in patients with compromised renal function [J].

Akers, Scott R. ;

Werner, Thomas J. ;

Rubello, Domenico ;

Alavi, Abass ;

Cheng, Gang .

NUCLEAR MEDICINE COMMUNICATIONS, 2016, 37 (08) :825-832

[2] Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukaemia Working Party [J].

Augustson, BM ;

Begum, G ;

Dunn, JA ;

Barth, NJ ;

Davies, F ;

Morgan, G ;

Behrens, J ;

Smith, A ;

Child, JA ;

Drayson, MT .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) :9219-9226

[3] F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma [J].

Bartel, Twyla B. ;

Haessler, Jeff ;

Brown, Tracy L. Y. ;

Shaughnessy, John D., Jr. ;

van Rhee, Frits ;

Anaissie, Elias ;

Alpe, Terri ;

Angtuaco, Edgardo ;

Walker, Ronald ;

Epstein, Joshua ;

Crowley, John ;

Barlogie, Bart .

BLOOD, 2009, 114 (10) :2068-2076

[4] FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 [J].

Boellaard, Ronald ;

Delgado-Bolton, Roberto ;

Oyen, Wim J. G. ;

Giammarile, Francesco ;

Tatsch, Klaus ;

Eschner, Wolfgang ;

Verzijlbergen, Fred J. ;

Barrington, Sally F. ;

Pike, Lucy C. ;

Weber, Wolfgang A. ;

Stroobants, Sigrid ;

Delbeke, Dominique ;

Donohoe, Kevin J. ;

Holbrook, Scott ;

Graham, Michael M. ;

Testanera, Giorgio ;

Hoekstra, Otto S. ;

Zijlstra, Josee ;

Visser, Eric ;

Hoekstra, Corneline J. ;

Pruim, Jan ;

Willemsen, Antoon ;

Arends, Bertjan ;

Kotzerke, Joerg ;

Bockisch, Andreas ;

Beyer, Thomas ;

Chiti, Arturo ;

Krause, Bernd J. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (02) :328-354

[5] Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group [J].

Cavo, Michele ;

Terpos, Evangelos ;

Nanni, Cristina ;

Moreau, Philippe ;

Lentzsch, Suzanne ;

Zweegman, Sonja ;

Hillengass, Jens ;

Engelhardt, Monika ;

Usmani, Saad Z. ;

Vesole, David H. ;

San-Miguel, Jesus ;

Kumar, Shaji K. ;

Richardson, Paul G. ;

Mikhael, Joseph R. ;

da Costa, Fernando Leal ;

Dimopoulos, Meletios-Athanassios ;

Zingaretti, Chiara ;

Abildgaard, Niels ;

Goldschmidt, Hartmut ;

Orlowski, Robert Z. ;

Chng, Wee Joo ;

Einsele, Hermann ;

Lonial, Sagar ;

Barlogie, Bart ;

Anderson, Kenneth C. ;

Rajkumar, S. Vincent ;

Durie, Brian G. M. ;

Zamagni, Elena .

LANCET ONCOLOGY, 2017, 18 (04) :E206-E217

[6] Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy [J].

Cho, Hyungwoo ;

Yoon, Dok Hyun ;

Lee, Jung Bok ;

Kim, Sung-Yong ;

Moon, Joon Ho ;

Do, Young Rok ;

Lee, Jae Hoon ;

Park, Yong ;

Lee, Ho Sup ;

Eom, Hyeon Seok ;

Shin, Ho-Jin ;

Min, Chang-Ki ;

Kim, Jin Seok ;

Jo, Jae-Cheol ;

Kang, Hye Jin ;

Mun, Yeung-Chul ;

Lee, Won Sik ;

Lee, Je-Jung ;

Suh, Cheolwon ;

Kim, Kihyun .

AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (12) :1280-1286

[7] Myeloma kidney: advances in molecular mechanisms of acute kidney injury open novel therapeutic opportunities [J].

Davenport, Andrew ;

Merlini, Giampaolo .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (10) :3713-3718

[8] Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit [J].

Dimopoulos, M. A. ;

Roussou, M. ;

Gavriatopoulou, M. ;

Fotiou, D. ;

Ziogas, D. C. ;

Migkou, M. ;

Panagiotidis, I. ;

Eleutherakis-Papaiakovou, E. ;

Kanellias, N. ;

Psimenou, E. ;

Marinaki, S. ;

Bacharaki, D. ;

Mparmparoussi, D. ;

Matsouka, C. ;

Giannouli, S. ;

Terpos, E. ;

Kastritis, E. .

BLOOD CANCER JOURNAL, 2017, 7 :e571-e571

[9] Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents [J].

Dimopoulos, M. A. ;

Delimpasi, S. ;

Katodritou, E. ;

Vassou, A. ;

Kyrtsonis, M. C. ;

Repousis, P. ;

Kartasis, Z. ;

Parcharidou, A. ;

Michael, M. ;

Michalis, E. ;

Gika, D. ;

Symeonidis, A. ;

Pouli, A. ;

Konstantopoulos, K. ;

Terpos, E. ;

Kastritis, E. .

ANNALS OF ONCOLOGY, 2014, 25 (01) :195-200

[10] The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma [J].

Dimopoulos, M. A. ;

Roussou, M. ;

Gkotzamanidou, M. ;

Nikitas, N. ;

Psimenou, E. ;

Mparmparoussi, D. ;

Matsouka, C. ;

Spyropoulou-Vlachou, M. ;

Terpos, E. ;

Kastritis, E. .

LEUKEMIA, 2013, 27 (02) :423-429

← 1 2 3 →